Published in Mult Scler on April 01, 2011
Disease-modifying treatments for multiple sclerosis - a review of approved medications. Eur J Neurol (2016) 1.12
Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis. Neuropsychiatr Dis Treat (2013) 0.79
Assessment of malignancy risk in patients with multiple sclerosis treated with intramuscular interferon beta-1a: retrospective evaluation using a health insurance claims database and postmarketing surveillance data. Ther Clin Risk Manag (2012) 0.78
Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial. Lancet Neurol (2011) 1.79
Pregnancy outcomes in multiple sclerosis following subcutaneous interferon beta-1a therapy. Mult Scler (2011) 1.19
Hepatic reactions during treatment of multiple sclerosis with interferon-beta-1a: incidence and clinical significance. Drug Saf (2003) 1.03
Haematological effects of interferon-beta-1a (Rebif) therapy in multiple sclerosis. Drug Saf (2004) 1.01
Molecular heterogeneity of familial myeloproliferative neoplasms revealed by analysis of the commonly acquired JAK2, CALR and MPL mutations. Fam Cancer (2014) 0.81
A multi-centre retrospective study of rituximab use in the treatment of relapsed or resistant warm autoimmune haemolytic anaemia. Br J Haematol (2013) 0.81
Subcutaneous interferon Beta-1a in pediatric multiple sclerosis: a retrospective study. J Child Neurol (2013) 0.79
Efficacy of subcutaneous interferon β-1a on MRI outcomes in a randomised controlled trial of patients with clinically isolated syndromes. J Neurol Neurosurg Psychiatry (2013) 0.78
Liver injury associated with the beta-interferons for MS. Neurology (2004) 0.75
Patient subgroup analyses of the treatment effect of subcutaneous interferon β-1a on development of multiple sclerosis in the randomized controlled REFLEX study. J Neurol (2014) 0.75
Comment on "Dimethyl Fumarate (Tecfidera): A New Oral Agent for Multiple Sclerosis" Ann Pharmacother (2014) 0.75